VRCAライブシグナル | Getagraph.comで利益を最大化

買う 109548 min ago

@ $5.55

発行日: 14 2月 2024 @ 00:00

リターン: 27.34%

前回のシグナル: 2月 10 - 01:12

前回のシグナル: 売る

リターン: 2.31 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:48):

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States...

Stats
本日の出来高	228 569
平均出来高	137 296
時価総額	299.53M
EPS	$0 ( 2024-02-29 )
次の収益日	( $-0.530 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.77
ATR14	$0.0470 (0.67%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Hayes Christopher G.	Buy	40 000	Common Stock
2024-03-15	Hayes Christopher G.	Buy	80 000	Employee Stock Option (right to buy)
2024-03-15	Goldenberg Gary	Buy	40 000	Common Stock
2024-03-15	Goldenberg Gary	Buy	80 000	Employee Stock Option (right to buy)
2024-03-15	Kohler Terry	Buy	80 000	Employee Stock Option (right to buy)

INSIDER POWER
90.98
Last 98 transactions
Buy: 14 420 498 \| Sell: 288 608

ボリューム相関

長: 0.03 (neutral)

短: 0.79 (moderate)

Signal:(47.262) Neutral

Verrica Pharmaceuticals 相関

10 最も正の相関
TGTX	0.959
IDCC	0.956
SLMBP	0.955
VBOCU	0.955
RAM	0.95
WKEY	0.95
OVLY	0.948
NCAC	0.947
MESA	0.946
GPACU	0.945

10 最も負の相関
CBNK	-0.945
CYTO	-0.939
GSMG	-0.938
GNTY	-0.936
BFRI	-0.936
FGBI	-0.936
GOOD	-0.934
AMNB	-0.93
CMLS	-0.929
ALHC	-0.927

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Verrica Pharmaceuticals 相関 - 通貨/商品

0.00
( neutral )

-0.66
( moderate negative )

0.00
( neutral )

0.14
( neutral )

-0.51
( weak negative )

0.61
( weak )

Verrica Pharmaceuticals 財務諸表

Annual	2023
収益:	$5.12M
総利益:	$3.96M (77.28 %)
EPS:	$-1.480

FY	2023
収益:	$5.12M
総利益:	$3.96M (77.28 %)
EPS:	$-1.480

FY	2022
収益:	$9.03M
総利益:	$8.31M (91.97 %)
EPS:	$-0.810

FY	2021
収益:	$12.00M
総利益:	$12.00M (100.00 %)
EPS:	$-1.300

Financial Reports:

No articles found.

Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.